X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BION-1301
Therapeutic Area: Immunology Product Name: BION-1301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
Cohort 2 in Part 3 of the ongoing phase 1/2 study will soon begin enrolling patients with IgAN utilizing subcutaneous administration of BION-1301.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BION-1301
Therapeutic Area: Immunology Product Name: BION-1301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability study in healthy volunteers.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
